Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction
Europace · 2026
DOI: 10.1093/europace/euag091 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Europace, 2026. Verfasst von Or Levi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Cell Biology, Faculty of Health Sciences, Ben-Gurion University of the Negev, David Ben-Gurion Blvd. 1, P.O. Box 653, Be…. Hauptthemen laut MEDLINE: Atrial Remodeling, Myocardial Infarction, Colchicine, Stroke Volume. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Israel Science Foundation, Israel Heart Society, Ben-Gurion University of the Negev.
Abstract (Originalsprache)
Aims
Atrial fibrillation (AF) is strongly associated with adverse outcomes, particularly in patients with heart failure (HF). AF susceptibility is driven by atrial remodelling, including electrical disarray, inflammation, and fibrosis, yet current therapies do not adequately target the underlying substrate. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and colchicine, a broad-spectrum anti-inflammatory agent, have demonstrated cardiovascular benefits, but their effects on atrial remodelling remain unclear. We evaluated the effects of both drugs on atrial remodelling in post-myocardial infarction (MI) rats with reduced ejection fraction. Methods and results Male rats underwent MI together with implantation of a chronic atrial pacing and recording system. One-week post-MI, animals with left ventricular ejection fraction ≤40% were randomized to semaglutide (40 µg/kg subcutaneously every 72 h), colchicine (100 µg/kg intraperitoneally daily), or vehicle for 21 days. Serial electrophysiological testing, echocardiography, histology, and molecular analyses were performed to characterize the AF substrate. Both semaglutide and colchicine reduced AF inducibility and AF duration, whereas semaglutide additionally reduced atrial signal complexity. Semaglutide attenuated atrial fibrosis, suppressed NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome expression, prevented connexin-43 (Cx43) lateralization, and reduced expression of the proarrhythmic small-conductance calcium-activated potassium channel 4 (SK4). Colchicine reduced NLRP3 and SK4 expression and inhibited p38, c-Jun N-terminal kinase (JNK), and protein kinase B (AKT) signalling, but did not prevent fibrosis or Cx43 remodelling.
Conclusion
In the post-MI HF setting, both drugs demonstrated anti-arrhythmic and anti-remodelling effects. Their differential actions suggest that multiple pathways can be targeted to limit AF substrate progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Cell Biology, Faculty of Health Sciences, Ben-Gurion University of the Negev, David Ben-Gurion Blvd. 1, P.O. Box 653, Beer-Sheva 8410501, Israel.
- Regenerative Medicine & Stem Cell Research Center, Ben-Gurion University of the Negev, David Ben-Gurion Blvd. 1, P.O. Box 653, Beer-Sheva 8410501, Israel.
- Department of Physiology and Pharmacology, Tel Aviv University, Tel Aviv, Israel.
- Inter-Departmental Core Facility, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Medical Engineering Unit, The Jerusalem College of Technology, Jerusalem, Israel.
- Cardiology Section, Soroka University Medical Center, Beer-Sheva, Israel.
ORCID-Profile: Or Levi, Noam Dalal, Aviv Komissar, Daniel Moldavsky, Salma Khamaisi, Sigal Elyagon, Michael Murninkas, Adir Eliyahu, Shira Burg, Bernard Attali, Daria Makarovsky, Gideon Gradwohl, Gal Tsaban, Yana Kakzanov, Avishag Laish-Farkash, Yoram Etzion
Förderung
- Israel Science Foundation
- Israel Heart Society
- Ben-Gurion University of the Negev
Zitieren
APA
Levi, O., Dalal, N., Komissar, A., Moldavsky, D., Khamaisi, S., Elyagon, S., Murninkas, M., Eliyahu, A., Burg, S., Attali, B., Makarovsky, D., Lichtenstein, A., Gradwohl, G., Tsaban, G., Kakzanov, Y., Laish-Farkash, A., Etzion, S., & Etzion, Y. (2026). Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction. Europace. https://doi.org/10.1093/europace/euag091
Vancouver
Levi O, Dalal N, Komissar A, Moldavsky D, Khamaisi S, Elyagon S, et al. Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction. Europace. 2026. doi:10.1093/europace/euag091
BibTeX
@article{Levi2026,
author = {Levi, Or and Dalal, Noam and Komissar, Aviv and Moldavsky, Daniel and Khamaisi, Salma and Elyagon, Sigal and Murninkas, Michael and Eliyahu, Adir and Burg, Shira and Attali, Bernard and Makarovsky, Daria and Lichtenstein, Alexandra and Gradwohl, Gideon and Tsaban, Gal and Kakzanov, Yana and Laish-Farkash, Avishag and Etzion, Sharon and Etzion, Yoram},
title = {Differential effects of semaglutide and colchicine on atrial remodeling in rats with reduced ejection fraction after myocardial infarction},
journal = {Europace},
year = {2026},
doi = {10.1093/europace/euag091}
}
EUVIMED